Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

BeiGene, Ltd. BGNE NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
73/100
5/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$258.00
+39.7%

BeiGene, Ltd. (BGNE) is a Biotechnology company in the Healthcare sector, currently trading at $184.71. It has a SharesGrow Score of 73/100, indicating a above average investment profile with 5 out of 7 criteria passed.

Analyst consensus target is BGNE = $258 (+39.7% upside).

Financials: revenue is $5.3B, +56.3%/yr average growth. Net income is $287M, growing at +75.8%/yr. Net profit margin is 5.4% (thin). Gross margin is 87.5% (+123.6 pp trend).

Balance sheet: total debt is $1.1B against $4.4B equity (Debt-to-Equity (D/E) ratio 0.25, conservative). Current ratio is 3.41 (strong liquidity). Debt-to-assets is 13.3%. Total assets: $8.2B.

Analyst outlook: 13 / 18 analysts rate BGNE as buy (72%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 83/100 (Pass), Moat 80/100 (Pass), Future 85/100 (Pass), Income 45/100 (Partial).

$258.00
▲ 39.68% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for BeiGene, Ltd., the average price target is $258.00, with a high forecast of $307.00, and a low forecast of $205.00.
Highest Price Target
$307.00
Average Price Target
$258.00
Lowest Price Target
$205.00

BGNE SharesGrow Score Overview

73/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 94/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 83/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 80/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 45/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BGNE

✓
VALUE Pass
94/100
BGNE trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $258, implying +39.7% from the current price $185. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
BGNE: +56.3%/yr revenue is, +75.8%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
BGNE: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
83/100
Balance sheet BGNE: Debt-to-Equity (D/E) ratio 0.25 (conservative), Current ratio is 3.41 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
80/100
BGNE: Gross margin is 87.5% (+123.6 pp trend), $20B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 80/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 13 / 18 analysts rate BGNE as buy (72%). Analyst consensus target is $258 (+39.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
~
INCOME Partial
45/100
BGNE: Net profit margin is 5.4%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range126.9681-248.16
Volume329.4K
Avg Volume (30D)357.77K
Market Cap$20.21B
Beta (1Y)0.63
Share Statistics
EPS (TTM)34.19
Shares Outstanding$109.06M
IPO Date2016-02-03
Employees10,600
CEOJohn V. Oyler
Financial Highlights & Ratios
Revenue (TTM)$5.34B
Gross Profit$4.67B
EBITDA$616.77M
Net Income$286.93M
Operating Income$447.14M
Total Cash$4.55B
Total Debt$1.09B
Net Debt$-3.45B
Total Assets$8.19B
Price / Earnings (P/E)5.4
Price / Sales (P/S)3.78
Analyst Forecast
1Y Price Target$283.00
Target High$307.00
Target Low$205.00
Upside+53.2%
Rating ConsensusBuy
Analysts Covering18
Buy 72% Hold 22% Sell 6%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS07725L1026

Price Chart

Track all markets on TradingView
BGNE
BeiGene, Ltd. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
126.97 52WK RANGE 248.16

People Also View

INCY
INCY
Incyte Corporation
$97.69
+2.24%
 ASND
ASND
Ascendis Pharma A/S
$249.84
+0.52%
 IONS
IONS
Ionis Pharmaceuticals, Inc.
$76.76
+2.41%
 BMRN
BMRN
BioMarin Pharmaceutical Inc.
$55.47
+1.08%
 RXDX
RXDX
Prometheus Biosciences, Inc.
$199.92
+0.09%
 ARWR
ARWR
Arrowhead Pharmaceuticals, Inc.
$66.69
+4.55%
 PCVX
PCVX
Vaxcyte, Inc.
$62.76
+1.64%
 IMGN
IMGN
ImmunoGen, Inc.
$31.24
+0.02%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message